A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin(®) in healthy Chinese male subjects

BACKGROUND: The biosimilar landscape for malignancies continues to grow, with several biosimilars for reference product bevacizumab currently available. Bevacizumab has been shown to be well tolerated; however, the safety of recombinant humanized anti-vascular endothelial growth factor (VEGF) monocl...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hongtao, Zhao, Xiangdi, Xie, Jing, Zhu, Xingyu, Su, Yue, He, Cuixia, Ding, Jiaxiang, Zhu, Minhui, Xu, Yuanyuan, Wang, Ying, Shan, Rongfang, Liu, Bingyan, Ding, Yuzhou, Liu, Yuanyuan, Zhou, Huan, Xie, Yunqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223897/
https://www.ncbi.nlm.nih.gov/pubmed/37245022
http://dx.doi.org/10.1186/s40360-023-00673-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223897/
https://www.ncbi.nlm.nih.gov/pubmed/37245022
http://dx.doi.org/10.1186/s40360-023-00673-y

Ejemplares similares